JP2021527045A5 - - Google Patents

Info

Publication number
JP2021527045A5
JP2021527045A5 JP2020567799A JP2020567799A JP2021527045A5 JP 2021527045 A5 JP2021527045 A5 JP 2021527045A5 JP 2020567799 A JP2020567799 A JP 2020567799A JP 2020567799 A JP2020567799 A JP 2020567799A JP 2021527045 A5 JP2021527045 A5 JP 2021527045A5
Authority
JP
Japan
Prior art keywords
patient
ethoxy
hydroxyethyl
pyridine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527045A (ja
JP7549344B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054743 external-priority patent/WO2019234689A1/en
Publication of JP2021527045A publication Critical patent/JP2021527045A/ja
Publication of JP2021527045A5 publication Critical patent/JP2021527045A5/ja
Application granted granted Critical
Publication of JP7549344B2 publication Critical patent/JP7549344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567799A 2018-06-06 2019-06-06 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 Active JP7549344B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382398 2018-06-06
EP18382398.8 2018-06-06
PCT/IB2019/054743 WO2019234689A1 (en) 2018-06-06 2019-06-06 Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Publications (3)

Publication Number Publication Date
JP2021527045A JP2021527045A (ja) 2021-10-11
JP2021527045A5 true JP2021527045A5 (https=) 2022-06-14
JP7549344B2 JP7549344B2 (ja) 2024-09-11

Family

ID=62716009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567799A Active JP7549344B2 (ja) 2018-06-06 2019-06-06 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法

Country Status (14)

Country Link
US (1) US20210308113A1 (https=)
EP (1) EP3801516A1 (https=)
JP (1) JP7549344B2 (https=)
KR (1) KR20210031435A (https=)
CN (1) CN112512524A (https=)
AU (1) AU2019283649A1 (https=)
BR (1) BR112020024917A2 (https=)
CA (1) CA3102407A1 (https=)
CL (1) CL2020003162A1 (https=)
EA (1) EA202092953A1 (https=)
IL (1) IL279183A (https=)
MX (1) MX2020013181A (https=)
SG (1) SG11202012045UA (https=)
WO (1) WO2019234689A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP3801515B1 (en) 2018-06-06 2025-04-09 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517186A (ja) 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
EA202091120A3 (ru) * 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma

Similar Documents

Publication Publication Date Title
JP2021527045A5 (https=)
JP2021527061A5 (https=)
JP6946477B2 (ja) アミノアルキルベンゾチアゼピン誘導体の用途
JP2021169519A5 (https=)
JP7510170B2 (ja) ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用
US20170144989A1 (en) Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
JP2019533642A5 (https=)
JP7549344B2 (ja) 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法
US12102644B2 (en) Compounds and methods of promoting myelination
JP2022516537A5 (https=)
US20180305396A1 (en) Deuterated compounds
CN102421454A (zh) 用于显像脂肪酸代谢和存储的pet放射性示踪剂
JP2015500294A (ja) 金属過剰症を治療する経口製剤
JP2021527049A (ja) ミトコンドリア性疾患の処置における使用のための５−［［４−［２−［５−（１−ヒドロキシエチル）ピリジン−２−イル］エトキシ］フェニル］メチル］−１，３−チアゾリジン−２，４−ジオンおよびその塩
AU2019238950B2 (en) Compounds for treating CNS- and neurodegenerative diseases
EP4470608A1 (en) Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis
CN107434799B (zh) 一种2-氨基-3-取代巯基丙酸酯衍生物，制备方法及其应用
HK40042762A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
EA047194B1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
HK40049546A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
WO2024245371A1 (zh) 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途
WO2024245370A1 (zh) 一种组合产品、盐及其用途
RU2021122694A (ru) Способы и композиции для лечения митохондриальной дисфункции
US20110178100A1 (en) Apoptosis inhibitor